AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30696755 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Stationary Walk Test associated with Virtual Reality (STVR-6)
Number of subjects: 50
Study 29126686 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion threshold of Hb 80 g/L
Number of subjects: 80
Study 29126686 — intervention group
Group type: COMPARATOR
Intervention: RBC transfusion threshold of Hb 100 g/L
Number of subjects: 80
Study 24933196 — intervention group
Group type: EXPERIMENTAL
Intervention: Admiral oxygenator (Group 1, G1)
Number of subjects: 30
Study 24933196 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB (Group 2, G2)
Number of subjects: 30
Study 24606873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Anorexia Nervosa (CBT-AN)
Number of subjects: 63
Study 24606873 — intervention group
Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 63
Study 22768456 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness training (5 sessions)
Number of subjects: 89
Study 22768456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 22768456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 89
Study 21298125 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational hypertension group (n=17)
Number of subjects: 48
Study 21298125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestational hypertension group (n=14)
Number of subjects: 48
Study 21298125 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 48
Study 21298125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive women with preeclampsia
Number of subjects: 48
Study 21298125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive women without preeclampsia
Number of subjects: 48
Study 18008221 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (types 6, 11, 16, and 18)
Number of subjects: 17622
Study 16153520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography measuring diastolic‐to‐systolic blood flow velocity ratio (DSVR)
Number of subjects: 95
Study 16153520 — intervention group
Group type: COMPARATOR
Intervention: Thallium 201 single photon emission computed tomography
Number of subjects: 95
Study 11550961 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg doxycycline twice a day
Number of subjects: 66
Study 11550961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9013904 — intervention group
Group type: EXPERIMENTAL
Intervention: Knitted Dacron polyester graft impregnated with collagen
Number of subjects: 244
Study 9013904 — intervention group
Group type: COMPARATOR
Intervention: Thin-wall expanded reinforced PTFE graft
Number of subjects: 244
Study 7933707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (200 or 400 mg)
Number of subjects: 18
Study 7933707 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 18
Study 3284491 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-containing priming solutions
Number of subjects: 50
Study 3284491 — intervention group
Group type: COMPARATOR
Intervention: Nonglucose primes
Number of subjects: 50
Study 2012295 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 2012295 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 20
Study 1106289 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by clinic nutritionist and physician with the National Heart and Lung Institute's type IV diet for 6 weeks, then diet plus clofibrate for 18 weeks.
Number of subjects: 150
Study 1106289 — intervention group
Group type: EXPERIMENTAL
Intervention: Same treatment by private physician.
Number of subjects: 150
Study 1106289 — intervention group
Group type: COMPARATOR
Intervention: No intervention for 24 weeks, subjects advised of abnormality.
Number of subjects: 150
Study 31900135 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality teaching group
Number of subjects: 30
Study 31900135 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching group
Number of subjects: 30
Study 30126754 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography with incision and drainage
Number of subjects: 125
Study 30126754 — intervention group
Group type: COMPARATOR
Intervention: Physical examination alone with incision and drainage
Number of subjects: 125
Study 28917226 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily energy intake <50% of requirement (Group A)
Number of subjects: 72
Study 28917226 — intervention group
Group type: COMPARATOR
Intervention: Average daily energy intake >=50% of requirement (Group B)
Number of subjects: 72
Study 25776489 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle administration of bupivacaine (0.5%, 15 mL, 0.3 mL/s)
Number of subjects: 23
Study 25776489 — intervention group
Group type: COMPARATOR
Intervention: Catheter administration of bupivacaine (0.5%, 15 mL, 0.3 mL/s)
Number of subjects: 23
Study 25776489 — intervention group
Group type: COMPARATOR
Intervention: Catheter administration of bupivacaine in female patients
Number of subjects: 23
Study 24224403 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone nasal drops with positional and feeding changes
Number of subjects: 74
Study 24224403 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional and feeding changes
Number of subjects: 74
Study 24224403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 21785918 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pouch double tract (SPDT)
Number of subjects: 0
Study 21785918 — intervention group
Group type: COMPARATOR
Intervention: Long pouch double tract (LPDT)
Number of subjects: 0
Study 19954717 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombo (EIPICO, Egypt) 75 mg tablets
Number of subjects: 32
Study 19954717 — intervention group
Group type: COMPARATOR
Intervention: Plavix (Sanofi Pharma/Bristol‐Myers Squibb, Paris, France) 75 mg tablets
Number of subjects: 32
Study 19954717 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombo (EIPICO, Egypt) 75 mg tablets (clopidogrel carboxylic acid metabolite)
Number of subjects: 32
Study 19954717 — intervention group
Group type: COMPARATOR
Intervention: Plavix (Sanofi Pharma/Bristol‐Myers Squibb, Paris, France) 75 mg tablets (clopidogrel carboxylic acid metabolite)
Number of subjects: 32
Study 16765700 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol‐dorzolamide combination
Number of subjects: 16
Study 16765700 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol‐pilocarpine combination
Number of subjects: 16
Study 15257114 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural beta-carotene
Number of subjects: 0
Study 15257114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11312403 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath transfer factor (TCO)
Number of subjects: 68
Study 11312403 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer coefficient (KCO)
Number of subjects: 68
Study 11312403 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol measurements
Number of subjects: 68
Study 9273873 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer (meso‐2, 3‐dimercaptosuccinic acid) at a daily dose of 30 mg/kg for five days
Number of subjects: 50
Study 9273873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7936800 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler sonography (TCD)
Number of subjects: 0
Study 7936800 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 0
Study 7936800 — intervention group
Group type: COMPARATOR
Intervention: MRA
Number of subjects: 0
Study 3222686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 80
Study 3222686 — intervention group
Group type: EXPERIMENTAL
Intervention: (+/-)-nicardipine (20 mg)
Number of subjects: 80
Study 3222686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg) and (+/-)-nicardipine (20 mg)
Number of subjects: 80
Study 29079414 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT guidance during pPCI
Number of subjects: 201
Study 29079414 — intervention group
Group type: COMPARATOR
Intervention: Angio-guided pPCI
Number of subjects: 201
Study 28874646 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular flap
Number of subjects: 50
Study 28874646 — intervention group
Group type: COMPARATOR
Intervention: Envelope flap
Number of subjects: 50
Study 28874646 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 26083696 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided skiing intervention (12 weeks, average of 25.5 days of skiing)
Number of subjects: 31
Study 26083696 — intervention group
Group type: COMPARATOR
Intervention: Control group (no skiing intervention)
Number of subjects: 31
Study 22111872 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete dentures (CCDs)
Number of subjects: 122
Study 22111872 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained overdentures (IODs)
Number of subjects: 122
Study 21473839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel (Elmex gel)
Number of subjects: 20
Study 21473839 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser + fluoride gel
Number of subjects: 20
Study 21473839 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser before fluoride application
Number of subjects: 20
Study 21473839 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 20
Study 18408986 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser irradiation (1 W of power in de‐focused continuous mode)
Number of subjects: 15
Study 18408986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-thermal gel)
Number of subjects: 15
Study 16684124 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 84
Study 16684124 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of imatinib
Number of subjects: 84
Study 15575343 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (360 mg/d)
Number of subjects: 144
Study 15575343 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine (10 mg/d)
Number of subjects: 144
Study 15575343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Orlistat and Sibutramine
Number of subjects: 144
Study 15575343 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 144
Study 15575343 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 144
Study 11573635 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective spinal anaesthesia (SSA)
Number of subjects: 40
Study 11573635 — intervention group
Group type: COMPARATOR
Intervention: Propofol general anaesthesia (GA)
Number of subjects: 40
Study 9782075 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg m-2 paclitaxel administered by 3-hour infusion
Number of subjects: 13
Study 7929727 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient management with early, ultrasound-guided trans-abdominal paracentesis, intravenous hydration, fluid removal of 1-3 liters over 2-3 hours.
Number of subjects: 18
Study 7929727 — intervention group
Group type: COMPARATOR
Intervention: Conservative management with hospitalization, intravenous hydration, and supportive therapy.
Number of subjects: 18
Study 3281014 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (day 3)
Number of subjects: 179
Study 3281014 — intervention group
Group type: COMPARATOR
Intervention: Conventional discharge (days 7 to 10)
Number of subjects: 179
Study 31580702 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA Knowledge and Attitudes (OSAKA) questionnaire
Number of subjects: 120
Study 31580702 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA Knowledge and Attitudes in Children (OSAKA-KIDS) questionnaire
Number of subjects: 120
Study 31580702 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in OSA diagnosis and management
Number of subjects: 120
Study 31580702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing practices
Number of subjects: 120
Study 30982686 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel)
Number of subjects: 716
Study 30982686 — intervention group
Group type: COMPARATOR
Intervention: ECF/ECX (epirubicin and cisplatin with fluorouracil or capecitabine)
Number of subjects: 716
Study 28851373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic lifestyle modification programme (P-LSM)
Number of subjects: 3539
Study 28851373 — intervention group
Group type: COMPARATOR
Intervention: Control lifestyle modification (C-LSM)
Number of subjects: 3539
Study 25744288 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Care intervention
Number of subjects: 47
Study 25744288 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 23425051 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid injection and balloon dilatation
Number of subjects: 43
Study 23425051 — intervention group
Group type: COMPARATOR
Intervention: Steroid application and balloon dilatation
Number of subjects: 43
Study 21729834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Cypher® stent (SES)
Number of subjects: 127
Study 21729834 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting Endeavor® stent (ZES)
Number of subjects: 127
Study 18832295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 to 200 mg qd
Number of subjects: 60
Study 18832295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 200 mg qd
Number of subjects: 60
Study 16384760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg 5 times daily)
Number of subjects: 87
Study 16384760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 15631798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g i.v. before and after surgery)
Number of subjects: 190
Study 15631798 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone plus sulbactam (sulperazon) (2 g i.v. before and after surgery)
Number of subjects: 190
Study 15631798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 190
Study 15631798 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone plus sulbactam (sulperazon)
Number of subjects: 190
Study 11052511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 percent diltiazem gel
Number of subjects: 30
Study 11052511 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 percent bethanechol gel
Number of subjects: 30
Study 9353681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention focused on low-fat eating pattern changes among 134 EFNEP participants.
Number of subjects: 204
Study 9353681 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education materials provided to 70 comparison participants (Control group).
Number of subjects: 204
Study 9353681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention among 134 EFNEP participants.
Number of subjects: 204
Study 1524960 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-feedback controlled infusion of ranitidine (maximum dose 800 mg 24 h-1)
Number of subjects: 10
Study 1524960 — intervention group
Group type: COMPARATOR
Intervention: fixed-dose infusion of ranitidine (0.25 mg kg-1 h-1)
Number of subjects: 10
Study 1524960 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-feedback controlled infusion of ranitidine
Number of subjects: 10
Study 1524960 — intervention group
Group type: COMPARATOR
Intervention: fixed-rate infusion of ranitidine
Number of subjects: 10
Study 1524960 — intervention group
Group type: COMPARATOR
Intervention: fixed-dose infusion of ranitidine
Number of subjects: 10
Study 3890864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 3890864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30281086 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT2go (cognitive behavioral therapy combined with automated thought challenging/adaptive behavior)
Number of subjects: 255
Study 30281086 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Monitoring (single-session illness psychoeducation with self-monitoring of symptoms)
Number of subjects: 255
Study 30281086 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 255
Study 30281086 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT2go
Number of subjects: 255
Study 30281086 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Monitoring (SM)
Number of subjects: 255
Study 29979388 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive blood-saving strategy
Number of subjects: 86
Study 29979388 — intervention group
Group type: COMPARATOR
Intervention: Traditional routine CPB
Number of subjects: 86
Study 25301224 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-based assessment of moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 176
Study 25301224 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported assessment of moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 176
Study 25301224 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-based assessment of sedentary time
Number of subjects: 176
Study 25301224 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported assessment of sedentary time
Number of subjects: 176
Study 23646468 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb powder (5-10 g dissolved in 40 mL warm water, administered nasally 2-3 times daily for 10 days)
Number of subjects: 40
Study 23646468 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine Western medical treatment)
Number of subjects: 40
Study 23646468 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb powder
Number of subjects: 40
Study 20932581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV; model FP7)
Number of subjects: 276
Study 20932581 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt glaucoma implant (BGI; model 101-350)
Number of subjects: 276
Study 19241772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.4% (Acular LS)
Number of subjects: 30
Study 19241772 — intervention group
Group type: COMPARATOR
Intervention: Refresh Tears (placebo)
Number of subjects: 30
Study 17520467 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg weekly for 12 weeks
Number of subjects: 24
Study 17520467 — intervention group
Group type: EXPERIMENTAL
Intervention: E-test for in vitro susceptibility
Number of subjects: 24
Study 15074089 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingling oral liquid (JLOL)
Number of subjects: 60
Study 15074089 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of human chorionic gonadotropine (hCG)
Number of subjects: 60
Study 11176258 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol
Number of subjects: 600
Study 11176258 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 600
Study 11176258 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 600
Study 11176258 — intervention group
Group type: COMPARATOR
Intervention: Iotrolan
Number of subjects: 600
Study 9720158 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent ICA clipping (performed in 6 cases, 1.3% of all surgeries)
Number of subjects: 470
Study 9720158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative bleeding from aneurysms of the ophthalmic segment of ICA (19 cases)
Number of subjects: 470
Study 9720158 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent ICA clipping (in cases of intraoperative bleeding)
Number of subjects: 470
Study 9720158 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent ICA clipping (6 patients)
Number of subjects: 470
Study 9688036 — intervention group
Group type: COMPARATOR
Intervention: 10 mg triamcinolone acetonide
Number of subjects: 57
Study 9688036 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide
Number of subjects: 57
Study 1807994 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rinn positioner
Number of subjects: 211
Study 1807994 — intervention group
Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 211
Study 1807994 — intervention group
Group type: COMPARATOR
Intervention: Rinn positioner
Number of subjects: 211
Study 1807994 — intervention group
Group type: COMPARATOR
Intervention: HPL device
Number of subjects: 211
Study 6336794 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training and dietary changes
Number of subjects: 23
Study 30446275 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pegylated liposomal doxorubicin (NPLD) + carboplatin (AUC 5 mg/min.mL, dose escalation from 40 to 50 mg/m2)
Number of subjects: 87
Study 30446275 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pegylated liposomal doxorubicin (NPLD) + carboplatin
Number of subjects: 87
Study 29558756 — intervention group
Group type: EXPERIMENTAL
Intervention: Network consulting room management (video, voice, text, electronic prescriptions)
Number of subjects: 240
Study 29558756 — intervention group
Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 240
Study 26411859 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) using a polyglycolide membrane
Number of subjects: 18
Study 26411859 — intervention group
Group type: COMPARATOR
Intervention: Access Flap (AF) surgery
Number of subjects: 18
Study 24078107 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo/WL
Number of subjects: 0
Study 24078107 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone/WL
Number of subjects: 0
Study 24078107 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Neutral
Number of subjects: 0
Study 24078107 — intervention group
Group type: EXPERIMENTAL
Intervention: WL (vs Neutral)
Number of subjects: 0
Study 22459773 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard management pathway based on evidence‐based cough algorithm
Number of subjects: 346
Study 19995131 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (114 g)
Number of subjects: 20
Study 19995131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempeh (206 g)
Number of subjects: 20